Oral Carbapenem: A New Last-Resort Antibiotic Pill

For decades, carbapenems have been the most powerful class of antibiotics in medicine, reserved for life-threatening infections that shrug off other drugs. They have also been available only as intravenous infusions, meaning patients needed a hospital bed or an IV line at home to receive them. That changed in 2024, when the U.S. Food and Drug Administration approved the first oral carbapenems for urinary tract infections: tebipenem pivoxil hydrobromide, followed by sulopenem etzadroxil with probenecid (brand name Orlynvah). The arrival of these pills opens a genuine new treatment option for drug-resistant infections, but it also raises questions about whether putting a “last-resort” antibiotic in pill form could accelerate the very resistance problem carbapenems were meant to solve.

Why an Oral Carbapenem Took So Long

Carbapenems work because they combine several advantages other antibiotics lack. They penetrate bacterial cell walls efficiently, resist breakdown by the enzymes that many resistant bacteria produce, and bind tightly to the proteins bacteria need to maintain their structure.¹ That potency, however, comes packaged in a molecule that the gut does not absorb well. Meropenem, imipenem, ertapenem, and doripenem all break down in stomach acid or pass through the intestine without being absorbed in meaningful amounts.

The solution is a chemical trick called a prodrug. Chemists attach a molecular “disguise” to the carbapenem that helps it survive the stomach and cross the intestinal lining. Once it reaches the bloodstream, enzymes strip away the disguise and release the active antibiotic. Early prodrug versions of carbapenems were explored in the 1990s, but most were hydrolyzed too quickly in the blood or had erratic absorption.² Researchers also tried this approach with meropenem, synthesizing ester prodrugs with greater fat-solubility to improve absorption, but stability proved difficult to balance.³

Tebipenem pivoxil cracked this problem. Its pivoxil ester form is absorbed at a rate higher than other prodrug-type antibiotics in its class, facilitated by active transport proteins in the intestinal lining.⁴ Sulopenem etzadroxil uses a different ester prodrug paired with probenecid, a drug that slows kidney excretion and keeps blood levels higher for longer. The two pills reached the market by different chemical routes, and their clinical profiles are not identical.

What the Trials Show for Tebipenem

The landmark trial for tebipenem pivoxil hydrobromide was ADAPT-PO, published in the New England Journal of Medicine. Patients with complicated urinary tract infections or acute kidney infections received either oral tebipenem (600 mg three times daily) or intravenous ertapenem (1 g once daily) for seven to ten days. Roughly 59% of tebipenem patients had an overall response, compared with about 62% of ertapenem patients, a gap well within the range that qualified tebipenem as noninferior. Clinical cure rates were nearly identical: about 93% in both groups. The difference in overall response was driven largely by patients who had bacteria reappear in their urine without any symptoms, a finding that did not translate into treatment failure. Side effects were also comparable, with mild diarrhea and headache being the most common complaints in both arms.⁵

A second large trial, PIVOT-PO, tested tebipenem against intravenous imipenem-cilastatin and confirmed similar results. Overall response was about 59% for tebipenem versus 60% for the IV comparator, with comparable outcomes even among patients whose infections were caused by bacteria producing extended-spectrum enzymes that destroy many other antibiotics. The safety profile remained consistent, and no new concerning signals appeared.⁶ Taken together, these two phase 3 trials established that an oral pill could hold its own against the IV carbapenems doctors already trusted for serious urinary infections.

Sulopenem and Its Different Niche

Sulopenem etzadroxil reached FDA approval specifically for uncomplicated urinary tract infections in adult women, a narrower indication than tebipenem’s. Its clinical program had a more complicated journey. In a trial comparing oral sulopenem to ciprofloxacin for uncomplicated UTI, sulopenem proved superior in women whose infections were caused by bacteria resistant to ciprofloxacin, with overall success rates of about 63% versus 36%. But when the bacteria were susceptible to ciprofloxacin, sulopenem fell short, at roughly 67% versus 79%.⁷ When looking at all patients combined, regardless of susceptibility, sulopenem met the statistical bar for noninferiority.

The picture was less favorable for complicated UTIs. A separate trial pitting intravenous sulopenem (followed by oral sulopenem step-down) against ertapenem (followed by oral ciprofloxacin) did not establish noninferiority. The gap was again driven by higher rates of bacteria showing up in the urine without symptoms in the sulopenem group, rather than by worse clinical outcomes: clinical success rates at the end of treatment were about 89% and 88%, respectively.⁸ This is why sulopenem’s approval landed on uncomplicated UTIs rather than the complicated infections where tebipenem earned its indication.

A more recent trial compared sulopenem to amoxicillin-clavulanate for uncomplicated UTI. Sulopenem met noninferiority in the overall population and showed a modest numerical advantage (roughly 62% versus 55% overall success), though it came with more frequent mild side effects.⁹ The FDA approval of Orlynvah made sulopenem the first oral penem-type antibiotic marketed in the United States.¹⁰

Activity Against Drug-Resistant Bacteria

The reason oral carbapenems generate excitement goes beyond convenience. They target bacteria that have evolved resistance to first-line antibiotics. Tebipenem’s potency against common urinary tract pathogens, including strains that produce extended-spectrum enzymes and plasmid-borne resistance factors, matches meropenem in laboratory tests.¹¹ For patients infected with bacteria resistant to fluoroquinolones, trimethoprim-sulfamethoxazole, and older cephalosporins, the only prior option was an IV carbapenem, which typically meant either a hospital stay or outpatient IV therapy with its costs and complications.

There is an important limit, though. These oral carbapenems are not designed for bacteria that have already become resistant to carbapenems themselves. Carbapenem-resistant Enterobacterales, the organisms that prompted the World Health Organization to classify antibiotic resistance as a critical global threat, produce enzymes called carbapenemases that break down the entire class, oral versions included.¹² Oral carbapenems fill the gap between older oral antibiotics that no longer work and the IV carbapenems that still do. They do not leap beyond the class’s existing ceiling.

The Community Resistance Concern

Until now, carbapenem use has been concentrated inside hospitals, where antibiotic stewardship teams can monitor prescriptions, track resistance patterns, and intervene when carbapenems are used unnecessarily. Putting these drugs in pill form shifts that selection pressure into the community, where monitoring is far less structured. An expert review of oral penem agents warned that growing use could amplify carbapenem resistance outside hospital walls, and called for strict resistance surveillance and formulary restrictions limiting these drugs to confirmed multidrug-resistant infections that lack other oral alternatives.¹³

This is not a theoretical worry. Hospital stewardship programs already work to restrict IV carbapenems. One system-wide evaluation of carbapenem restriction required prescribers to complete an electronic form justifying the order, with pharmacist review and an algorithm recommending alternatives when the justification did not hold up.¹⁴ That kind of infrastructure does not exist in outpatient clinics and urgent care centers. A scoping review of oral penems noted that broader oral carbapenem use might promote carbapenem resistance and alter intestinal flora in ways that are harder to track in the community setting.¹⁵

The tension is real and probably unresolvable in the abstract. Every new antibiotic faces the same paradox: the more it is used, the faster resistance develops. With oral carbapenems, the stakes are higher because carbapenems represent the last reliable class for many resistant infections. Whether community prescribing can be kept disciplined enough to preserve their utility is one of the defining stewardship questions of the next decade.

Side Effects and Gut Health

In the major trials, tebipenem and sulopenem had side effect profiles similar to their IV comparators. Roughly a quarter of patients in the ADAPT-PO tebipenem trial experienced some adverse event, most commonly mild diarrhea and headache, matching the ertapenem comparison group almost exactly.⁵ Sulopenem showed a slightly higher rate of mild adverse events compared to amoxicillin-clavulanate.⁹

A broader concern is what oral broad-spectrum antibiotics do to the gut microbiome. Antibiotic-driven disruption of intestinal bacteria creates favorable conditions for opportunistic infections, most worryingly C. difficile, which causes severe diarrhea and colitis.¹⁶ A network analysis comparing C. difficile risk across antibiotic classes found that imipenem-cilastatin carried roughly four times the odds of C. difficile infection compared to piperacillin-tazobactam, with a trend toward higher risk than meropenem as well.¹⁷ That study examined IV carbapenems specifically, and we do not yet have large-scale data on whether oral carbapenems carry the same degree of gut-flora disruption. But because oral dosing delivers the drug directly through the intestine before it reaches the bloodstream, the theoretical exposure of gut bacteria to active drug is at least as great as with IV administration, and possibly greater before the prodrug is fully absorbed.

The Valproate Interaction

One drug interaction stands out as genuinely dangerous and applies to the entire carbapenem class, oral versions included. Carbapenems slash blood levels of valproic acid, an anticonvulsant used to manage epilepsy and bipolar disorder. A meta-analysis found that adding a carbapenem to valproate therapy dropped valproate blood levels by an average of about 44 mg/L, with the drop appearing within one to three days. Seizure frequency increased by more than a quarter during combination treatment. Valproate levels took one to two weeks to recover after the carbapenem was stopped.¹⁸ For IV carbapenems, this interaction was already well known in hospital pharmacies. With oral carbapenems prescribed in outpatient settings, the risk of this interaction being missed rises if prescribers are less familiar with carbapenem pharmacology than hospital-based physicians and pharmacists.

Dosing and Kidney Function

Tebipenem is dosed at 600 mg three times daily, typically for seven to ten days.¹⁹ Sulopenem etzadroxil is taken with probenecid, which extends the drug’s time in the body. Both drugs are cleared primarily by the kidneys. In a study of tebipenem across various degrees of kidney impairment, patients with end-stage kidney disease on dialysis had roughly seven times the drug exposure of patients with normal function. Four hours of dialysis reduced blood levels by about 40%.²⁰ Dose adjustments are needed when kidney function falls below a certain threshold, and clinicians prescribing these pills need to check renal function just as they would for other renally cleared antibiotics.

Early pharmacokinetic work with the carbapenem prodrug DZ-2640 (the compound that became tebipenem) showed that urinary recovery ranged from about 32% to 45% of the dose, with renal clearance far exceeding normal filtration rates, indicating that the kidneys actively pump the drug into the urine.²¹ That active tubular secretion is actually a therapeutic advantage for urinary infections, because it concentrates the drug exactly where it is needed. But it also means that any reduction in kidney function has an outsized effect on how much drug lingers in the blood.

The Hospital Discharge Angle

One practical benefit of oral carbapenems that gets less attention than resistance debates is what they mean for hospital stays. Patients with resistant urinary infections currently face a choice: remain hospitalized for IV antibiotics or go home with a peripherally inserted central catheter (PICC line) and home infusion services. PICC lines carry their own risks, including bloodstream infections and blood clots, and home infusion is expensive and logistically burdensome. A retrospective study of patients with infections caused by carbapenem-resistant organisms found that those switched to oral antibiotics had a median hospital stay of 14 days, compared with 16 days for patients who continued IV therapy, though the difference was not statistically significant in that particular cohort.²² That study looked at oral switch therapy broadly, not oral carbapenems specifically, but it illustrates the broader principle: getting patients off IV antibiotics earlier is a win for comfort, safety, and cost, even when the stay-reduction is modest.

The savings extend beyond the hospital bill. Home IV infusion services in the United States can cost thousands of dollars per week, and patients on home IV antibiotics require nursing visits, supplies, and monitoring. An oral pill eliminates all of that infrastructure. For straightforward urinary infections where the pathogen is susceptible, the ability to treat at home with a pill rather than in a hospital with an IV is a meaningful quality-of-life improvement.

Pediatric Experience From Japan

The United States is not the first country to use oral tebipenem. Japan approved tebipenem pivoxil for pediatric ear, nose, throat, and respiratory infections years ago, providing a window into real-world use that the U.S. clinical trials could not. In a study of 49 children with community-acquired pneumonia treated with a three-day course of tebipenem pivoxil, 32 of 36 evaluable patients were cured within two weeks. Fever dropped significantly within a day of starting treatment, and inflammatory markers fell within two to four days. Only six children experienced mild diarrhea, and no serious adverse events were reported.²³ The Japanese pediatric experience is reassuring for safety, though U.S. approvals so far cover adult urinary tract infections rather than pediatric respiratory infections.

Japan’s longer experience with the drug also provides an informal test case for resistance fears. The drug has been available there since 2009, and while Japanese antibiotic stewardship practices differ from those in the United States, the country has not reported a dramatic surge in carbapenem resistance attributable to oral tebipenem use. That is encouraging but not conclusive, since prescribing volumes, population density, and resistance ecology all differ between countries.

Global Regulatory Fragmentation

Both oral carbapenems are now approved in the United States, but their global availability remains uneven. One expert commentary described global regulatory fragmentation and evidence limited to urinary tract infections as key barriers to broader clinical use.¹³ The irony is that the patients who stand to benefit most from an oral last-resort antibiotic, those in low- and middle-income countries with high burdens of drug-resistant infections and limited IV infrastructure, may be the last to gain access. Regulatory pathways, pricing negotiations, and the economics of antibiotic manufacturing all work against rapid global rollout for drugs targeting resistant infections, which by definition should be prescribed sparingly.

Meanwhile, the clinical evidence base remains narrow. Both approved drugs have been tested almost exclusively against urinary tract infections. Whether oral carbapenems can serve as step-down therapy for bloodstream infections, intra-abdominal infections, or hospital-acquired pneumonia once initial IV treatment has stabilized a patient is an open question that future trials will need to address. Until that evidence arrives, prescribers in the United States have a powerful but specifically scoped new tool: a pill that can treat complicated or drug-resistant urinary infections without an IV line, provided it is used with the restraint its class demands.